Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ATIR after haploidentical CD34-selected peripheral blood stem cell transplantation
NL-OMON36698Phase 2Active, not recruiting
- Sponsor
- Kiadis Pharma
- Start
- Feb 2011
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATIR101 and TH9402 in hematopoietic malignancies, leukemia, lymphoma and 5 more, sponsored by Kiadis Pharma. Primary endpoints: Transplant-related mortality at 6 months and Transplant-related mortality at 12 months. Started Feb 2011; status: active, not recruiting.
02
Drugs
ATIR101TH9402
03
Conditions
hematopoietic malignanciesleukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON36698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36698.